CARD14

Across TCGA pan-cancer cohorts, CARD14 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CARD14 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CARD14 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CARD14 expression acts as an unfavorable survival marker.

OV, ACC, and HNSC are the cancer types where CARD14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	IV	0.076	0.759	.014	12	view →
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
HNSC	OS	Median	III,IV	0.087	0.746	<.001	12	view →
READ	DFS	Median	All	0.162	0.720	.019	9	view →
LUSC	OS	Median	All	0.138	0.776	.008	9	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CARD14–OV (OS)

Open the OV breakdown →